KAPAHealthcare · BiotechnologyThe 2 Wall Street analysts covering Kairos Pharma Ltd. hold a median 12-month price target of $7 — +629.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 37 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Kairos Pharma Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (97): Smaller than most of the companies we track.
Momentum (3): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on KAPA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +629.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 4 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 20 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 7 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 19 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
| 16 July 2025 | D. Boral Capital | Maintains | Buy | — |
| 4 June 2025 | D. Boral Capital | Maintains | Buy | — |
| 17 Apr 2025 | D. Boral Capital | Maintains | Buy | — |
| 3 Apr 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 31 Mar 2025 | D. Boral Capital | Maintains | Buy | — |
| 27 Mar 2025 | Maxim Group | Initiates | Buy | — |
| 20 Mar 2025 | D. Boral Capital | Maintains | Buy | — |
| 26 Feb 2025 | D. Boral Capital | Maintains | Buy | — |
| 18 Feb 2025 | D. Boral Capital | Maintains | Buy | — |
| 12 Feb 2025 | D. Boral Capital | Maintains | Buy | — |
| 22 Jan 2025 | D. Boral Capital | Maintains | Buy | — |
| 14 Nov 2024 | D. Boral Capital | Maintains | Buy | — |
| 14 Oct 2024 | EF Hutton | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KAPA appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, Kairos Pharma Ltd. returned −89.5% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 88% of US stocks
Cheaper than 81% of US stocks
Cheaper than 63% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 12% of US stocks
Higher than 5% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Kairos Pharma Ltd. has a market value of $2.9M and an enterprise value of $1.3M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$5.8M.
Free cash flow in the twelve months to 30 June 2026: −$4.0M.
Trailing P/E: −3.0×; forward P/E: −0.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Kairos Pharma Ltd. employs 1 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Kairos Pharma Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Kairos Pharma announced interim efficacy results from its ongoing Phase 2 trial evaluating ENV-105 alongside apalutamide in patients with metastatic castration-resistant prostate cancer.
Why it matters — The update concerns clinical results for a Kairos Pharma drug candidate being tested in prostate cancer.
Kairos Pharma reported positive interim efficacy data from its Phase 2 trial of ENV-105 (carotuximab) combined with apalutamide in patients with metastatic castration-resistant prostate cancer. The interim analysis showed a statistically significant difference in progression-free survival.
Why it matters — The interim findings provide an update on a clinical-stage program being evaluated by Kairos Pharma.
Kairos Pharma announced that its President and Chief Scientific Officer, Neil Bhowmick, will present and moderate a discussion in person at the 24th Annual Discovery on Target Drug Discovery Conference, held Sept. 28 to Oct. 1 at the Sheraton Boston Hotel, with sessions available on demand online.
Why it matters — A KAPA watcher would care because presenting and moderating at a major drug discovery conference raises the company's visibility within the industry.
Kairos Pharma announced that CEO and Chairman John Yu, MD, will present a corporate overview in person at the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 14-16, 2026 at the Lotte New York Palace Hotel. Yu's presentation is set for September 14, 2026 at 4:00 PM Eastern Time.
Why it matters — A KAPA watcher would care because the company's presentation at a major investment conference offers visibility and an opportunity to communicate its corporate overview to the investment community.
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced a 1-for-7 reverse stock split of its outstanding common shares. The split is expected to become effective on September 1, 2026 at 12:01 a.m. ET, with shares expected to begin trading on the NYSE American on a split-adjusted basis at that time.
Why it matters — A reverse stock split will consolidate Kairos Pharma's outstanding shares, changing its share count and per-share price, which matters to shareholders tracking the company's capital structure.
The 2 Wall Street analysts covering Kairos Pharma Ltd. have a median 12-month price target of $7, with estimates ranging from $2 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering Kairos Pharma Ltd., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kairos Pharma Ltd. 37 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Kairos Pharma Ltd. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (97 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +629.5% from the last close, and Ticker Nerd's factor model ranks Kairos Pharma Ltd. 37 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Kairos Pharma Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KAPA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $12 over the next 12 months.
Kairos Pharma Ltd. returned -89.5% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company focused on developing cancer therapeutics that address immune suppression and drug resistance.
The most recent item we track (Benzinga, 6 Oct 2026): "Kairos Pharma Targets Drug Resistance Mechanism Against Prostate Cancer". Kairos Pharma announced interim efficacy results from its ongoing Phase 2 trial evaluating ENV-105 alongside apalutamide in patients with metastatic castration-resistant prostate cancer.
Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company focused on developing cancer therapeutics that address immune suppression and drug resistance. The company’s current portfolio centers on oncology candidates such as antibodies and small molecules designed to support immune function and target difficult-to-treat cancers, including prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma Ltd. also works on immunotherapy and cell therapy approaches, reflecting its emphasis on mechanisms that may help improve treatment response in cancer patients. Based in Los Angeles, California, the company operates in the biotechnology and pharmaceuticals sector, where it contributes to the development of experimental treatments intended for use in specialized oncology settings.
CEO Dr. John S. Yu M.D., Ph.D. · 1 employees · United States · https://kairospharma.com
